InnoCare Pharma Limited
HKSE: 9969.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jisong Cui
- Employees
- 1,089
- Headquarters
- Beijing, China
- IPO year
- 2020
- Market cap
- HK$20.2B
- Website
- https://www.innocarepharma.com
Loading 9969…
Loading profile data…Frequently asked questions about 9969
What does InnoCare Pharma Limited (9969.HK) do?
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macr...
Where does 9969.HK trade?
InnoCare Pharma Limited (9969.HK) trades on the Hong Kong Stock Exchange.
What sector is 9969.HK in?
InnoCare Pharma Limited (9969.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of InnoCare Pharma Limited?
Jisong Cui is the chief executive officer of InnoCare Pharma Limited (9969.HK).
Where is InnoCare Pharma Limited headquartered?
InnoCare Pharma Limited is headquartered in China.
Does 9969.HK pay a dividend?
InnoCare Pharma Limited (9969.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 9969.HK go public?
InnoCare Pharma Limited (9969.HK) completed its initial public offering in 2020.